Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Managing Patient Expectations and ADC-Related Side Effects
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA, CPEL
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Care Team and Patient Resources and Tools for mBC
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA, CPEL
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Assurance in ADC Therapy for HER2+ or HER2-Low mBC
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA, CPEL
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
FDA Updates
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
Read More
FDA Updates
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
Read More
FDA Updates
Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation
Read More
FDA Updates
FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma
Read More
FDA Updates
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma
Read More
FDA Updates
Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer
Read More
FDA Updates
Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program
Read More
25
26
27
28
29
30
31
Page 28 of 196
Results 271 - 280 of 1953